Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor

• Type of Material: Article
• Authors: Sagar Lonial, Emory University; Nisha Joseph, Emory University; YT Tai, Harvard University; KC Anderson, Harvard University
• Language: English
• Date: 2021-01-01
• Publisher: Dove Medical Press Limited.
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Joseph et al.
• License: Creative Commons Attribution-Noncommercial 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.2147/CPAA.S288840
• Title of Journal or Parent Work: Clinical Pharmacology: Advances and Applications
• Volume: 13
• Start Page: 169
• End Page: 180
• Keywords: selinexor; relapsed/refractory myeloma; belamaf; belantamab mafodotin; myeloma
• Research Categories: Health Sciences, Oncology

Abstract

Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action. Here, we will review the most recent data on both belantamab mafodotin, an antibody drug conjugate (ADC) targeting BCMA, and selinexor, a first-in-class selective inhibitor of XPO1, as well as touch on some of the recently published data for other immunotherapies in development, namely bispecific T cell engagers, ADCs, and CAR-T cell therapies.